SCTbio Partners with CCRM Nordic to Advance Cell and Gene Therapy Development

• SCTbio has partnered with CCRM Nordic to advance manufacturing and development in the cell and gene therapy sector.

• The collaboration will provide integrated solutions, including process development, analytical services, and strategic support for early-stage companies.

SCTbio, a provider of cGMP manufacturing services for cell-based products, has announced a strategic partnership with CCRM Nordic, an organisation focused on accelerating regenerative medicine and cell and gene therapy commercialisation. This collaboration comes at a critical time for the cell and gene therapy industry, which faces increasing demand and challenges in scaling production and controlling costs.

The partnership aims to support early-stage cell therapy companies, particularly those in phase I/II development. By combining SCTbio’s expertise in cGMP manufacturing with CCRM Nordic’s infrastructure and analytical capabilities, the alliance will offer end-to-end solutions, including integrated process development, analytical services, and logistics support.

“This partnership represents more than just combining capabilities – it’s about creating a seamless pathway from innovation to patient impact,” said Luděk Sojka, CEO of SCTbio.

A key component of the collaboration is CCRM Nordic’s future 3,000 square metre laboratory facilities for analytical and process development, with a GMP facility scheduled to open in 2026. The initiative also leverages SCTbio’s established manufacturing services and access to a 150-strong apheresis network, offering a comprehensive ecosystem for advanced therapy medicinal products (ATMPs).

“Collaboration is essential to advance the cell therapy field,” added Fredrik Wessberg, CEO of CCRM Nordic. “This partnership strengthens our ability to support innovative companies and accelerate the development of next-generation therapies, ultimately bringing life-changing treatments to patients faster.”